ACR 2026 RheumNow Lupus Topic Compilation c Save
Kidney Transplantation in Lupus
Treating joints and weight together TOGETHER PSA
Belimumab and Rituximab for SLE A Successful Trial
Silent Drifts Non adherence and inflammation in SLE
Drugs in Lupus Nephritis Save Kidney Function, Increase Survival
Three Factors Shape Vaccine Response in Immune-Mediated Inflammatory Disease
Transcription
This is an ACR twenty twenty six podcast coming to you from ACR in Orlando. Hope you enjoy it. Great rheumatologists go to great meetings like this. RoomNow live twenty twenty seven is happening January 3031 in Dallas, Texas. Join your colleagues from across the country and around the world for an interactive, engaging, and practice changing event.
Go to roomnow.live to see the full program and register today.
Hello. My name is Rinalini Day. I'm a fellow in rheumatology and internal medicine based in London in The UK, and I'm delighted to be here reporting for RheumNow from ACR twenty twenty six. So when lupus nephritis progresses to kidney failure, two important questions can arise. So can that patient access a kidney transplant in the first place, and how well does the transplanted kidney survive?
So Laura Plantinga and I are presenting two abstracts, which will be presented on Monday of the convergence, addressing these questions using data from The United States Renal Data System. Both compare SLE with other immune mediated inflammatory diseases which cause kidney failure. So first, the abstract which I will be presenting on Monday is one eight six four, which examined transplant access in more than eighteen thousand adults starting treatment for end stage kidney disease between 2013 and 2021. So patients with SLE had higher odds of receiving a preemptive transplant, and that is before starting dialysis, and of being waitlisted by the start of kidney failure treatments. These differences persisted after adjusting for socioeconomic and clinical factors.
Once dialysis had begun, however, the apparent advantages in time to waitlisting and transplantation were no longer statistically significant after adjusting. So the findings differed depending on which stage of the transplant pathway was actually examined. The second study, which will be presented after me by Laura Plantinga, is 1865, and this examined graft failure in nearly five thousand six hundred adults receiving their first kidney transplant. So before adjustment, the hazard ratio of graft failure was equivalent to forty seven percent higher in recipients with SLE compared to the people with other inflammatory diseases. But after accounting for age, sex, and race, there was no statistically significant difference compared with recipients whose kidney failure was attributed to other IMiDs.
The initial difference should therefore not simply be attributed to the lupus itself. So what can we as rheumatologists actually take from all of this data? So transplantation is already the preferred treatment for suitable patients with lupus related kidney failure as per the ACR guidelines. Discussions with nephrology and transplant teams should begin early, including whether assessment can proceed before dialysis becomes necessary. That's really the gold standard of how to manage these patients.
These findings provide reassurance, though, that a lupus diagnosis alone should not be taken to mean that there is poorer graft survival at the end. Rheumatologists have a role in helping suitable patients reach transplantation and remaining involved afterwards coordinating their lupus care with the transplant team and nephrology teams. If you'd like to know more about these abstracts, they are abstracts one eight six four and one eight six five being presented in the lupus session on Monday. And if you'd like to know more about everything happening here at Convergence, don't forget to follow RheumNow. Thank you.
Welcome back. This is Chiha Li reporting from RheumNow for ACR twenty twenty six. In my earlier video, I talked about how obesity affects drug levels, clearance and we may be perhaps under dosing our older adults. And I raised the question also that GLP-1s are commonly in use, and what does that mean in terms of disease activity and drug use and activity? And I think one of the most anticipated and possibly highly bookmarked abstract is abstract number 2,942.
This is the Together Psoriatic Arthritis Study. And it provides some insights because it is a randomized study of combining izikizumab with tirzepatide or using izikizumab alone, and asking the question of does adding on a dual GIP GLP-one agent improve disease activity and outcomes? So this involved two seventy one patients. On average, they had a BMI of about thirty eight, And about twenty percent of these patients failed two or more ages before they were put on the ezikizumab. And this is actually an extension study.
We saw earlier reports of this at the thirty sixth mark, and this abstract is looking at an extended outcome measure at fifty two weeks. So what did they find? Well, ACR fifty was forty four percent with the combination group compared to just sixteen percent in isekizumab alone. ACR twenty similarly had a seventy three percent improvement versus thirty six percent in the alone group. Minimal disease activity also improved along with swollen joint counts, tender joint counts, and weight loss of course was marked.
In the combination group, there was a 20% reduction in body weight over the fifty two weeks compared to just point 0%. So maybe perhaps lifestyle alone is not enough, and we consistently see that. Metabolic measures improved as well, triglycerides, blood pressure, and A1C as well. Reassuringly, safety was comparable between the two groups. Now, let me push on this just a little bit because we did see promising results from thirty six weeks, and this was the open level, open label extension of it.
So some of the improvements may... We see may be just expectations from it. And the other thing to keep in mind is some of the outcome measures are subjective. However, they did also have tender joint, swollen joint count, an objective to balance that out. Notably, ACR seventy was not all that different between the two groups.
So there's some moderate effect, but not to the level of ACR70. And one thing that I want to also raise is that this was starting izikizumab and tirzepatide at the same time together. And there wasn't any analysis to separate whether the benefits were from the tirzepatide or izikizumab, because especially at the beginning stages, a lot of this could be from the biologic modification. Another question I want to raise though is with the 20% weight loss, again towards the tail end of it, how much of this is coming from the drug or the weight changes with the decrease in inflammatory fat cells. But regardless, I think the important thing that we are consistently throwing...
Seeing throughout the ACR 26 is the theme of obesity and that it is potentially a modifying factor in disease activity and drug response and that it's something that we should treat together in our patients with inflammatory arthritis, particularly psoriatic arthritis, given the higher prevalence there. Thank you for listening. This is Chi Hai Lee, reporting from RheumNow.
Hi. I'm Andrea Fava coming to you from Orlando at ACR twenty twenty six, and I want to tell you about a late breaking abstract that was presented this morning by the Leiden Group, the last author is Ono Tang, and that's a SymBioS-two, a very clever investigator initiated trial. So in the past many have tried combining Rituximab and Balimumab in lupus nephritis or lupus and failing. Now this trial did not This trial had a very interesting design. Was seventy six patients randomized, it was open label with severe lupus.
They could have nephritis or not have nephritis. One arm, the placebo arm, had mycophenolate and prednisone with mycophenolate monotherapy for the duration of the two years. The other group had Volumumab for four weeks and then at week four they started getting Rituximab and then another dose of Rituximab at six weeks while Volumiob is being continued. Mycophenolate was also added but it was started to be tapered after six months. What you see is that this patient, one group that continues Mycophenolate and the other group that has Mycophenolate at the beginning some rituximab and then they stay on Bolivia for two years.
And then they looked at different outcomes. The primary endpoint of the trial was treatment failure. Not the regular SRI4 or BCLA, it was failure to treatment and that could have been because the drug was discontinued, patient had a flare for many different reasons. Now, in the first year, the two groups did exactly the same. The rate of response was the same.
But in the second year that's where the real difference changed. The patient who remained in belimumab had much less treatment failures compared to the people who were on mycophenolate monotherapy. More or less seventy four percent of the people who got belimumab did not fail as compared to maybe twenty five percent. And if you look at outcomes such as lupus nephritis, it was quite impressive. I believe it was in the fifty plus percent complete response rate at the end of the trial as compared to only twenty five percent.
Now, do we need this? Is this in the setting of modern combination therapy? I think it's quite clever because think about it, these patients start on aggressive treatment and then you taper Mycophenolate. You don't give Rituximab anymore and they stay on Bolivimab which is very safe. If you think about young women who may have lupus nephritis and then have a desire for pregnancy that can place them in a good place.
On the other hand the comparator was just mycophenolate and maybe it's not a true modern treatment with combination therapy but you have to remember that this trial has been going on for a long time, it's investigator initiated So I think it's quite important. Safety, pretty much the same, a little more COVID in patients who got bulimia with rituximab, especially in the first year. So I think overall it's a very interesting concept. It's going to challenge how we think about treating lupus and it speaks to this need to go very hard at the beginning because it can help us cooling down the disease and then we can stay on safer medication later. If you want to learn more, go on roomnow.com.
Hi. I'm Sheila Reyes from The Philippines, and I'm here at ACR twenty twenty six reporting for RheumNow in Orlando, Florida. Today, I will be sharing an interesting study that I found primarily because it has, I feel, it has significant impact on patients but garners less attention compared to pharmacologic treatment or diagnostic tests in patients with SLE. And this is abstract number two two four two by the group of doctor Sun from Duke University on nonadherence and active inflammation in SLE. Now this was a cross sectional analysis of an SLE registry which characterized and looked into the effect of nonadherence and inflammatory activity on symptom burden in patients with SLE.
So just for a quick background, we know, that there was already an established model, two models for SLE type one, which is, more driven by inflammation, and type two, symptom burden, characterized by mood, sleep change, anything that affects quality of life. So the methods of the study, they stratified patients according to adherence status and inflammatory disease. In terms of inflammatory disease, this was either a high type one or a low type one. And there were four nineteen unique patient visits. Almost half of the patients reported non adherence and about twenty percent had high type one activity.
Now among the non adherent patients, those with high type one activity cited cost and forgetfulness or forgetting as adherence barriers. And additionally, in that same subgroup, those who were non adherent with high type one activity, patients were younger, more likely to be black, Hispanic, low income, and less likely to be married or cohabitating. They also had the highest rates of moderate to severe fatigue, cognitive dysfunction, poor sleep, depression, and higher emergency room visits and hospitalizations. Now, this study also found that taken individually, nonadherence and active inflammation were associated with symptom burden, but taken together, that risk increases more. So what do these findings tell us?
Well, a multitude of factors come into play in SLE beyond disease activity and societal societal factors like cost, affordability, and access pushes the treatment gap further. And, these socially vulnerable factors can lead to uncontrolled disease, which eventually also result to higher inflammatory burden. I mean, if a drug is proven effective and safe, but if the patient is unable to afford it or no access to it, it... And it then it renders treatment useless in a sense. Thank you.
Follow me on x at RheumNow for more updates of ACR twenty twenty six.
Hi. It's doctor Janet Pope at Janet Bourdeaux talking here at RheumNow, and I hope you're following us at ACR twenty twenty six, the live coverage at the, wonderful ACR conference in Orlando. I wanted to talk about lupus nephritis and systemic lupus overall and how drugs can save lives and preserve kidney function. So the first poster I wanna talk about is number one two three two. So doctor H.
Clark presented on obinutuzumab. We already know about the obinutuzumab, RCT, and lupus nephritis, and this is on the overall patients looking at their urine and then on about the sixty patients that had renal biopsies at the beginning and at the end plan to look at things. So she looked at a biomarker, EGF, and this is... Can be looked at in the urine and it's inversely correlated with tubular health. So if it goes up, that's, like you want it to go in the better direction.
And what she found was that basically urinary EGF was, modest inverse correlation at baseline with, what was going on from the point of view of their active lupus nephritis. And it was correlated with the NIH Chronicity Index when they looked again at week seventy six, not as much correlated with, activity. And this is a marker that is more inter interstitium, so interstitial nephritis, if you have that. On top of GI, you have more renal failure. So then they looked at the renal biopsies that were paired, about thirty patients on obinutuzumab and about thirty at standard of care in the RCT as a planned subset analysis.
What was really interesting and unexpected was the urinary EGF and also on the renal biopsies improved on obinutuzumab in both responders, no surprising, but also nonresponders on renal biopsy, but it did not improve on placebo in the nonresponders. Take home message, this might be something important for damage that is above and beyond activity and chronicity index. I wanna talk briefly about two other posters. Number one two three one, doctor, Ron Van Vollenhoven, a big giant in lupus, looked at five year mortality on belimumab. So this was a cohort mandated by the FDA years ago to make sure belimumab was safe over the next five years.
So they had over two thousand patients with belimumab and almost a thousand controls with, with lupus who weren't on belimumab. This, by the way, wasn't renal lupus. It was all... It was lupus. So it didn't have to be lupus nephritis.
What was the take home? Not only was it safe, it actually reduced the five year mortality. The five year mortality overall wasn't high in either group, but in every way you slice and dice the follow-up, it was less five year mortality if you're on belimumab. In that note as well, poster one two two nine by, doctor Michelle Petrie looked at belimumab and lupus nephritis data. So this is the observed lupus nephritis cohort.
There's sixty one patients. They're still enrolling. And what she found, and and I'm not surprised at all, was in the real world, belimumab, did function to help lupus nephritis the way it did in trials. What do I mean by that? Belimumab plus standard of care had a high partial and complete renal responder, and also it had higher high remission rates, and it had low flares and low, low renal worsening, so a lot of renal preservation.
Now I say compared to what because it's a it's a a single, a single arm study, but I think that that is showing that the data that she showed and this preliminary analysis was about the same data you would see within the RCTs. Take home message, we have to treat our patients effectively. We wanna treat to a target, but we can show survival of organ function survival, survival overall of, mortality, reduced mortality in our patients with lupus. Thank you and please follow us for more coverage at, RheumNow.
Hey, everyone. I'm Ehike Damoling. I'm here in Orlando at our coverage for RheumNow at ACR twenty twenty six. I'm here with Felizia Mota. I'm here with Viviane Souza.
And Viviane will talk more about her study.
So let's talk about registry from the Brazilian Society of Rheumatology. That's a very important study. And let's talk about what shaped the answer, the response to vaccination in patients with SARD? Viviani?
Yep. This is an important study, the safety cohort, and this is sub analysis of this register. And we are evaluating the humoral response and the inflammatory status of our patients in relation with the SARS CoV two vaccines response.
And how many patients and what were the diagnosis?
In this this SOBI analysis, we included more than 500 participants. We had 214 patients, mainly lupus patients, about fifty percent of our sample. And we included three hundred and sixty healthy controls. And it's important to highlight that all the sample was naive before the infection and did... Were not vaccinated before being included in the study.
Vivian, and what were the main results of this study?
Well, the main results, the first main result is that our patients, they have a lower response when we compare to health controls. We evaluated the three vaccine platforms, the Sinovac, CoronaVac vaccine, the Adenovirus vaccine, the AstraZeneca, and the mRNA vaccine, the Pfizer vaccine. And in our patients, the coronavirus was the one that had the worst response, while the Pfizer vaccine was least influenced by the the... Had a a better response than the other platforms.
And what are the key messages for our audience in RheumNow?
And we have... Before going to the key messages, we have another survey analysis that we had a comparison between high and low d z... Degree of immunosuppression. And to all the platforms, vaccine platforms, less with the Pfizer platform, we had a worse response in patients who had a higher degree of immunosuppression. And a third result of our study is that we evaluated soluble mediators, 27 soluble mediators to see...
To analyze the inflammatory status. And what we saw that the inflammatory profile of the patients was different at baseline from the healthy controls, and this influenced the, vaccine response. So, those who were good responders, they had a profile that was more... With a higher predominance of the innate immune system mediators, while the... Those who who had worse response had more an inflammatory profile.
So let's go to the key... One key message for our...
One key message. Our patients, the vaccine responses influenced not for only one factor, but the disease itself, the degree of immunosuppression that these patients are exposed to, The plat... Vaccine platform, we had a different response. Pfizer seems better. And also to the inflammatory basal profile.
So thank you very much and stay tuned for more.
Go to roomnow.live to see the full program and register today.
Hello. My name is Rinalini Day. I'm a fellow in rheumatology and internal medicine based in London in The UK, and I'm delighted to be here reporting for RheumNow from ACR twenty twenty six. So when lupus nephritis progresses to kidney failure, two important questions can arise. So can that patient access a kidney transplant in the first place, and how well does the transplanted kidney survive?
So Laura Plantinga and I are presenting two abstracts, which will be presented on Monday of the convergence, addressing these questions using data from The United States Renal Data System. Both compare SLE with other immune mediated inflammatory diseases which cause kidney failure. So first, the abstract which I will be presenting on Monday is one eight six four, which examined transplant access in more than eighteen thousand adults starting treatment for end stage kidney disease between 2013 and 2021. So patients with SLE had higher odds of receiving a preemptive transplant, and that is before starting dialysis, and of being waitlisted by the start of kidney failure treatments. These differences persisted after adjusting for socioeconomic and clinical factors.
Once dialysis had begun, however, the apparent advantages in time to waitlisting and transplantation were no longer statistically significant after adjusting. So the findings differed depending on which stage of the transplant pathway was actually examined. The second study, which will be presented after me by Laura Plantinga, is 1865, and this examined graft failure in nearly five thousand six hundred adults receiving their first kidney transplant. So before adjustment, the hazard ratio of graft failure was equivalent to forty seven percent higher in recipients with SLE compared to the people with other inflammatory diseases. But after accounting for age, sex, and race, there was no statistically significant difference compared with recipients whose kidney failure was attributed to other IMiDs.
The initial difference should therefore not simply be attributed to the lupus itself. So what can we as rheumatologists actually take from all of this data? So transplantation is already the preferred treatment for suitable patients with lupus related kidney failure as per the ACR guidelines. Discussions with nephrology and transplant teams should begin early, including whether assessment can proceed before dialysis becomes necessary. That's really the gold standard of how to manage these patients.
These findings provide reassurance, though, that a lupus diagnosis alone should not be taken to mean that there is poorer graft survival at the end. Rheumatologists have a role in helping suitable patients reach transplantation and remaining involved afterwards coordinating their lupus care with the transplant team and nephrology teams. If you'd like to know more about these abstracts, they are abstracts one eight six four and one eight six five being presented in the lupus session on Monday. And if you'd like to know more about everything happening here at Convergence, don't forget to follow RheumNow. Thank you.
Welcome back. This is Chiha Li reporting from RheumNow for ACR twenty twenty six. In my earlier video, I talked about how obesity affects drug levels, clearance and we may be perhaps under dosing our older adults. And I raised the question also that GLP-1s are commonly in use, and what does that mean in terms of disease activity and drug use and activity? And I think one of the most anticipated and possibly highly bookmarked abstract is abstract number 2,942.
This is the Together Psoriatic Arthritis Study. And it provides some insights because it is a randomized study of combining izikizumab with tirzepatide or using izikizumab alone, and asking the question of does adding on a dual GIP GLP-one agent improve disease activity and outcomes? So this involved two seventy one patients. On average, they had a BMI of about thirty eight, And about twenty percent of these patients failed two or more ages before they were put on the ezikizumab. And this is actually an extension study.
We saw earlier reports of this at the thirty sixth mark, and this abstract is looking at an extended outcome measure at fifty two weeks. So what did they find? Well, ACR fifty was forty four percent with the combination group compared to just sixteen percent in isekizumab alone. ACR twenty similarly had a seventy three percent improvement versus thirty six percent in the alone group. Minimal disease activity also improved along with swollen joint counts, tender joint counts, and weight loss of course was marked.
In the combination group, there was a 20% reduction in body weight over the fifty two weeks compared to just point 0%. So maybe perhaps lifestyle alone is not enough, and we consistently see that. Metabolic measures improved as well, triglycerides, blood pressure, and A1C as well. Reassuringly, safety was comparable between the two groups. Now, let me push on this just a little bit because we did see promising results from thirty six weeks, and this was the open level, open label extension of it.
So some of the improvements may... We see may be just expectations from it. And the other thing to keep in mind is some of the outcome measures are subjective. However, they did also have tender joint, swollen joint count, an objective to balance that out. Notably, ACR seventy was not all that different between the two groups.
So there's some moderate effect, but not to the level of ACR70. And one thing that I want to also raise is that this was starting izikizumab and tirzepatide at the same time together. And there wasn't any analysis to separate whether the benefits were from the tirzepatide or izikizumab, because especially at the beginning stages, a lot of this could be from the biologic modification. Another question I want to raise though is with the 20% weight loss, again towards the tail end of it, how much of this is coming from the drug or the weight changes with the decrease in inflammatory fat cells. But regardless, I think the important thing that we are consistently throwing...
Seeing throughout the ACR 26 is the theme of obesity and that it is potentially a modifying factor in disease activity and drug response and that it's something that we should treat together in our patients with inflammatory arthritis, particularly psoriatic arthritis, given the higher prevalence there. Thank you for listening. This is Chi Hai Lee, reporting from RheumNow.
Hi. I'm Andrea Fava coming to you from Orlando at ACR twenty twenty six, and I want to tell you about a late breaking abstract that was presented this morning by the Leiden Group, the last author is Ono Tang, and that's a SymBioS-two, a very clever investigator initiated trial. So in the past many have tried combining Rituximab and Balimumab in lupus nephritis or lupus and failing. Now this trial did not This trial had a very interesting design. Was seventy six patients randomized, it was open label with severe lupus.
They could have nephritis or not have nephritis. One arm, the placebo arm, had mycophenolate and prednisone with mycophenolate monotherapy for the duration of the two years. The other group had Volumumab for four weeks and then at week four they started getting Rituximab and then another dose of Rituximab at six weeks while Volumiob is being continued. Mycophenolate was also added but it was started to be tapered after six months. What you see is that this patient, one group that continues Mycophenolate and the other group that has Mycophenolate at the beginning some rituximab and then they stay on Bolivia for two years.
And then they looked at different outcomes. The primary endpoint of the trial was treatment failure. Not the regular SRI4 or BCLA, it was failure to treatment and that could have been because the drug was discontinued, patient had a flare for many different reasons. Now, in the first year, the two groups did exactly the same. The rate of response was the same.
But in the second year that's where the real difference changed. The patient who remained in belimumab had much less treatment failures compared to the people who were on mycophenolate monotherapy. More or less seventy four percent of the people who got belimumab did not fail as compared to maybe twenty five percent. And if you look at outcomes such as lupus nephritis, it was quite impressive. I believe it was in the fifty plus percent complete response rate at the end of the trial as compared to only twenty five percent.
Now, do we need this? Is this in the setting of modern combination therapy? I think it's quite clever because think about it, these patients start on aggressive treatment and then you taper Mycophenolate. You don't give Rituximab anymore and they stay on Bolivimab which is very safe. If you think about young women who may have lupus nephritis and then have a desire for pregnancy that can place them in a good place.
On the other hand the comparator was just mycophenolate and maybe it's not a true modern treatment with combination therapy but you have to remember that this trial has been going on for a long time, it's investigator initiated So I think it's quite important. Safety, pretty much the same, a little more COVID in patients who got bulimia with rituximab, especially in the first year. So I think overall it's a very interesting concept. It's going to challenge how we think about treating lupus and it speaks to this need to go very hard at the beginning because it can help us cooling down the disease and then we can stay on safer medication later. If you want to learn more, go on roomnow.com.
Hi. I'm Sheila Reyes from The Philippines, and I'm here at ACR twenty twenty six reporting for RheumNow in Orlando, Florida. Today, I will be sharing an interesting study that I found primarily because it has, I feel, it has significant impact on patients but garners less attention compared to pharmacologic treatment or diagnostic tests in patients with SLE. And this is abstract number two two four two by the group of doctor Sun from Duke University on nonadherence and active inflammation in SLE. Now this was a cross sectional analysis of an SLE registry which characterized and looked into the effect of nonadherence and inflammatory activity on symptom burden in patients with SLE.
So just for a quick background, we know, that there was already an established model, two models for SLE type one, which is, more driven by inflammation, and type two, symptom burden, characterized by mood, sleep change, anything that affects quality of life. So the methods of the study, they stratified patients according to adherence status and inflammatory disease. In terms of inflammatory disease, this was either a high type one or a low type one. And there were four nineteen unique patient visits. Almost half of the patients reported non adherence and about twenty percent had high type one activity.
Now among the non adherent patients, those with high type one activity cited cost and forgetfulness or forgetting as adherence barriers. And additionally, in that same subgroup, those who were non adherent with high type one activity, patients were younger, more likely to be black, Hispanic, low income, and less likely to be married or cohabitating. They also had the highest rates of moderate to severe fatigue, cognitive dysfunction, poor sleep, depression, and higher emergency room visits and hospitalizations. Now, this study also found that taken individually, nonadherence and active inflammation were associated with symptom burden, but taken together, that risk increases more. So what do these findings tell us?
Well, a multitude of factors come into play in SLE beyond disease activity and societal societal factors like cost, affordability, and access pushes the treatment gap further. And, these socially vulnerable factors can lead to uncontrolled disease, which eventually also result to higher inflammatory burden. I mean, if a drug is proven effective and safe, but if the patient is unable to afford it or no access to it, it... And it then it renders treatment useless in a sense. Thank you.
Follow me on x at RheumNow for more updates of ACR twenty twenty six.
Hi. It's doctor Janet Pope at Janet Bourdeaux talking here at RheumNow, and I hope you're following us at ACR twenty twenty six, the live coverage at the, wonderful ACR conference in Orlando. I wanted to talk about lupus nephritis and systemic lupus overall and how drugs can save lives and preserve kidney function. So the first poster I wanna talk about is number one two three two. So doctor H.
Clark presented on obinutuzumab. We already know about the obinutuzumab, RCT, and lupus nephritis, and this is on the overall patients looking at their urine and then on about the sixty patients that had renal biopsies at the beginning and at the end plan to look at things. So she looked at a biomarker, EGF, and this is... Can be looked at in the urine and it's inversely correlated with tubular health. So if it goes up, that's, like you want it to go in the better direction.
And what she found was that basically urinary EGF was, modest inverse correlation at baseline with, what was going on from the point of view of their active lupus nephritis. And it was correlated with the NIH Chronicity Index when they looked again at week seventy six, not as much correlated with, activity. And this is a marker that is more inter interstitium, so interstitial nephritis, if you have that. On top of GI, you have more renal failure. So then they looked at the renal biopsies that were paired, about thirty patients on obinutuzumab and about thirty at standard of care in the RCT as a planned subset analysis.
What was really interesting and unexpected was the urinary EGF and also on the renal biopsies improved on obinutuzumab in both responders, no surprising, but also nonresponders on renal biopsy, but it did not improve on placebo in the nonresponders. Take home message, this might be something important for damage that is above and beyond activity and chronicity index. I wanna talk briefly about two other posters. Number one two three one, doctor, Ron Van Vollenhoven, a big giant in lupus, looked at five year mortality on belimumab. So this was a cohort mandated by the FDA years ago to make sure belimumab was safe over the next five years.
So they had over two thousand patients with belimumab and almost a thousand controls with, with lupus who weren't on belimumab. This, by the way, wasn't renal lupus. It was all... It was lupus. So it didn't have to be lupus nephritis.
What was the take home? Not only was it safe, it actually reduced the five year mortality. The five year mortality overall wasn't high in either group, but in every way you slice and dice the follow-up, it was less five year mortality if you're on belimumab. In that note as well, poster one two two nine by, doctor Michelle Petrie looked at belimumab and lupus nephritis data. So this is the observed lupus nephritis cohort.
There's sixty one patients. They're still enrolling. And what she found, and and I'm not surprised at all, was in the real world, belimumab, did function to help lupus nephritis the way it did in trials. What do I mean by that? Belimumab plus standard of care had a high partial and complete renal responder, and also it had higher high remission rates, and it had low flares and low, low renal worsening, so a lot of renal preservation.
Now I say compared to what because it's a it's a a single, a single arm study, but I think that that is showing that the data that she showed and this preliminary analysis was about the same data you would see within the RCTs. Take home message, we have to treat our patients effectively. We wanna treat to a target, but we can show survival of organ function survival, survival overall of, mortality, reduced mortality in our patients with lupus. Thank you and please follow us for more coverage at, RheumNow.
Hey, everyone. I'm Ehike Damoling. I'm here in Orlando at our coverage for RheumNow at ACR twenty twenty six. I'm here with Felizia Mota. I'm here with Viviane Souza.
And Viviane will talk more about her study.
So let's talk about registry from the Brazilian Society of Rheumatology. That's a very important study. And let's talk about what shaped the answer, the response to vaccination in patients with SARD? Viviani?
Yep. This is an important study, the safety cohort, and this is sub analysis of this register. And we are evaluating the humoral response and the inflammatory status of our patients in relation with the SARS CoV two vaccines response.
And how many patients and what were the diagnosis?
In this this SOBI analysis, we included more than 500 participants. We had 214 patients, mainly lupus patients, about fifty percent of our sample. And we included three hundred and sixty healthy controls. And it's important to highlight that all the sample was naive before the infection and did... Were not vaccinated before being included in the study.
Vivian, and what were the main results of this study?
Well, the main results, the first main result is that our patients, they have a lower response when we compare to health controls. We evaluated the three vaccine platforms, the Sinovac, CoronaVac vaccine, the Adenovirus vaccine, the AstraZeneca, and the mRNA vaccine, the Pfizer vaccine. And in our patients, the coronavirus was the one that had the worst response, while the Pfizer vaccine was least influenced by the the... Had a a better response than the other platforms.
And what are the key messages for our audience in RheumNow?
And we have... Before going to the key messages, we have another survey analysis that we had a comparison between high and low d z... Degree of immunosuppression. And to all the platforms, vaccine platforms, less with the Pfizer platform, we had a worse response in patients who had a higher degree of immunosuppression. And a third result of our study is that we evaluated soluble mediators, 27 soluble mediators to see...
To analyze the inflammatory status. And what we saw that the inflammatory profile of the patients was different at baseline from the healthy controls, and this influenced the, vaccine response. So, those who were good responders, they had a profile that was more... With a higher predominance of the innate immune system mediators, while the... Those who who had worse response had more an inflammatory profile.
So let's go to the key... One key message for our...
One key message. Our patients, the vaccine responses influenced not for only one factor, but the disease itself, the degree of immunosuppression that these patients are exposed to, The plat... Vaccine platform, we had a different response. Pfizer seems better. And also to the inflammatory basal profile.
So thank you very much and stay tuned for more.

If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.